RGS22 is a novel testis specific protein (1). It inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form (2). RGS22 may be an important tumor suppressor protein in tumorigenesis, a potential new diagnostic and prognostic biomarker for metastasis and may translate to therapeutic opportunities for the preventive treatment of epithelial cancer metastasis (1).
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Researchers who bought this antibody have also purchased: